https://www.selleckchem.com/pr....oducts/17-DMAG,Hydro
Likewise, exacerbations were reduced. After 8 weeks of mepolizumab daily OCS doses were reduced from 6.25mg daily (0-2 at baseline to 2.5mg daily (0-11.9) at week 8 (P0.001). FEV1 remained generally unchanged during the course of the study. Eosinophil counts rapidly declined and remained at a low level during the observation period. No new safety signals were observed in this study. Mepolizumab improved asthma symptom control and had a steroid-sparing effect. Efficacy in this real-world study was comparable to R
پسند
تبصرہ
بانٹیں
